REGN — Regeneron Pharmaceuticals, Inc.

Is REGN overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of November 17, 2026

Regeneron Pharmaceuticals, Inc. (REGN) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $952.40. The rating moved from Neutral to Overbought on November 13, 2026.

See all overbought Healthcare stocks →

AI analysis

Regeneron combines a strong biologics commercial base with an active, diversified pipeline and a solid balance sheet. Recent market flows favor large‑cap pharma defensives, which supports near‑term share stability. Key upside drivers include successful late‑stage readouts, continued uptake of core products, and productive partnerships or bolt‑on deals. Main challenges are clinical and regulatory execution, pricing/reimbursement dynamics, and valuation sensitivity to any growth disappointment. Overall outlook is constructive provided pipeline milestones and commercial execution meet expectations, while investors should monitor regulatory developments and trial outcomes closely.

Key factors

  • Market leadership in high‑margin biologics with durable franchises that drive recurring revenue and strong cash generation
  • Broad and diversified R&D pipeline across ophthalmology, immunology, oncology and rare disease supported by proprietary platforms (enabling sustained innovation)
  • Defensive sector flows into large‑cap pharma creating near‑term support for share price amid risk‑off market tone
  • Strong balance sheet and cash flow profile that enable continued organic investment, partnerships and selective M&A
  • Favorable readthrough from positive large‑cap pharma data in the sector that reduces perceived clinical/regulatory downside for biologics
  • Commercial partnerships (co‑promotion and collaborations) that expand market access and reduce single‑product concentration risk

Risks

  • Clinical development risk: late‑stage trial failures or disappointing readouts could materially impact valuation
  • Pricing and reimbursement pressure, including Medicare/Medicare Advantage regulatory changes that could tighten drug coverage or increase compliance costs
  • Competitive threats from other large pharma and emerging biotech, especially in high‑growth therapeutic areas
  • High valuation sensitivity: elevated multiple implies downside if growth or margin assumptions slip
  • Revenue concentration risk if a small number of products drive a large share of sales and face generic/biologic competition or label changes
  • Regulatory, litigation, or supply‑chain disruptions that could delay launches or constrain sales

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for REGN — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.